Answers are grounded in this paper and cite their sources.
Human mesenchymal stem cells (MSCs) have emerged as attractive cellular vehicles to deliver therapeutic genes for ex-vivo therapy of diverse diseases; this is, in part, because they have the capability to migrate into tumor or lesion sites. Previously, we showed that MSCs could be utilized to deliver a bacterial cytosine deaminase (CD) suicide gene to brain tumors. Here we assessed whether transduction with a retroviral vector encoding CD gene altered the stem cell property of MSCs. MSCs were transduced at passage 1 and cultivated up to passage 11. We found that proliferation and differentiation potentials, chromosomal stability and surface antigenicity of MSCs were not altered by retroviral transduction. The results indicate that retroviral vectors can be safely utilized for delivery of suicide genes to MSCs for ex-vivo therapy. We also found that a single retroviral transduction was sufficient for sustainable expression up to passage 10. The persistent expression of the transduced gene indicates that transduced MSCs provide a tractable and manageable approach for potential use in allogeneic transplantation. Human blood, or mesenchymal, stem cells can be genetically manipulated to halt the growth of brain tumor cells without affecting the inherent ‘stemness’ of the engineered cells. A team led by Haeyoung Suh-Kim and Sung-Soo Kim at Ajou University School of Medicine, Korea, has transduced mesenchymal stem cells with a retrovirus expressing a bacterial enzyme called cytosine deaminase. This enzyme helps convert a non-toxic prodrug — a compound that must undergo chemical conversion before becoming an active — into a cancer-killing chemotherapy agent. In the presence of the prodrug, the transformed stem cells suppressed the growth of glioma, yet still maintained their chromosomal stability as well as proliferation and differentiation capacity. The findings highlight the potential of mesenchymal stem cells to deliver therapeutic genes with little worry that the gene therapy renders the stem cells more dangerous.
No takes yet. Share an insight, caveat, or question.
Park et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: